TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02740829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal glucagon
Description: Glucagon will be administered via a nasal dispenser

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Placebo
Study: NCT00626717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Riboflavin/UVA crosslinking
Description: Removal of epithelium. Riboflavin eye drops. UVA exposure.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Fluorescein eye drops. Exposure with blue light
Study: NCT03687658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laddr
Description: Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laddr
Description: Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences.
Study: NCT01684436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Punctal Plug
Description: Punctal plugs inserted into the study eye on Day 1.
Study: NCT00940836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resfenol
Description: Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine. Patients will receive up to five capsules a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group will receive placebo capsules up to five times a day, with the exact same taste and appearance as the active comparator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Co interventional acetaminophen
Description: All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
Study: NCT04393350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Mesylate
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00893841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole dihydrochloride
Description: tablets and caplets, take with liquid before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole dihydrochloride
Description: tablets and caplets, take with liquid before bedtime
Study: NCT00940836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co interventional acetaminophen
Description: All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
Study: NCT01176214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early tracheostomy
Description: Patients with supratentorial ICH who require mechanical ventilation, fulfill the inclusion criteria, and have been randomized to the treatment arm will receive an early tracheostomy within 72h after symptom onset.
Study: NCT00198471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitrase
Study: NCT05879952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + BTsN session
Description: BTsN treatment session included exercises aimed at identifying, finding, chasing or moving objects, with the aim of improving the perceptual-cognitive skills of each patient, through audio-visual stimuli and feedback implementing visuo-spatial skills and spatial cognition, allowing at the same time motor coordination and balance improvement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
Study: NCT04814953

Intervention type: OTHER
Intervention: questionnaires
Description: EQ-5D-5L questionnaire questioning their overall health on five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). In addition patients will have to fill in the generic 15D questioning 15 specific dimensions on 5 levels as well as the BaSQoL, which is a disease specific questionnaire for patients with KC. The Time-trade off task is the final question.
Study: NCT00925977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin NPH + Insulin Apidra: Active Comparator
Description: Insulin NPH + Insulin Apidra: Active Comparator
Study: NCT01471145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: naltrexone for extended-release injectable suspension, 380 mg/vial, every 4 weeks or once a month
Study: NCT02574442

Intervention type: DEVICE
Intervention: In Vivo Confocal Microscopy Probe
Description: Participants will have 2 areas on their cervical imaged by the confocal probe.
Study: NCT02974465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biofeedback Electromyography
Description: protocol of sEMG-BFB that consisted of active movements in glenohumeral abduction guided by the visual signal of the register equipment. The protocol was the following: firstly proof active movements were requested in glenohumeral abduction without feeling any pain in order to teach the visual signal of their muscle activity. The therapist dedicated around 10 minutes in each session for subject learned to control the activation of both muscles in the limits that physical therapist marked with each individual in particular (controlling the activation in the upper trapezius). Once integrated information, shoulder abduction were requested following 4 main principles.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Biofeedback Electromyography
Description: consisted of Sham-EMG biofeedback, in which the electrodes were placed as the same method as the EG (Fig. 2) but the screen emit no signal. The subject performed 3 sequences of 10 abduction contractions (first degrees) without pain feeling and with 5 minutes of rest between sequences.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conventional Physical Therapy Treatment
Description: All participants received a conventional daily treatment of neurological physical therapy. Since no evidence has been found about a specific therapy that specially could benefit hemiparesis consequences, the common approach in this center consists of a combination of different specific concepts (Bobath, Brunnstrom, Rood, Johnstone, Propioceptive Neuromuscular Facilitation, Perfetti, Vojta, Motor Relearning Programme,...), exercise programs, electrotherapy, myofascial techniques, etc...

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy Treatment
Description: All participants received a conventional daily treatment of neurological physical therapy. Since no evidence has been found about a specific therapy that specially could benefit hemiparesis consequences, the common approach in this center consists of a combination of different specific concepts (Bobath, Brunnstrom, Rood, Johnstone, Propioceptive Neuromuscular Facilitation, Perfetti, Vojta, Motor Relearning Programme,...), exercise programs, electrotherapy, myofascial techniques, etc...
Study: NCT01187784

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping Cat cognitive-behavioral therapy for anxious youth
Description: Manualized, empirically supported CBT treatment for anxious youth
Study: NCT02253537

Intervention type: DEVICE
Intervention: CST001
Study: NCT02678936

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Application of platelet-rich plasma during surgery
Study: NCT01176214

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late tracheostomy
Description: Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails
Study: NCT01112943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture on predefined points for 20min once a week over seven weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: a seven week pulmonary rehabilitation course
Study: NCT01967524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin A + ropivacaïne
Description: D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of botulinum toxin A associated with ropivacaïne~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaïne
Description: D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain Questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of ropivacaïne alone~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36).
Study: NCT02658344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JOINTSTEM
Description: Jointstem (Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml), 1 time injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution (Sodium chloride 9mg/ml), 1 time injection
Study: NCT01112943

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Twice a week for seven weeks. Each session lasting 2 hrs (1hr exercise and 1hr education
Study: NCT00605865

Intervention type: DRUG
Intervention: Sertraline hydrochloride
Description: J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501090, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 16 weeks after the first administration.
Study: NCT05314114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No axillary surgery
Description: No axillary surgery
Study: NCT00891371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide (Autogel formulation)
Description: Autogel 120mg
Study: NCT01706874

Intervention type: OTHER
Intervention: Periodontal prophylaxis
Description: Periodontal scaling (every 6 months) plus mouthrinses plus toothbrushing (twice daily). Removal of adherent plaque and calculus with ultrasonic instruments and hand instruments, such as periodontal scalers and curettes, and polishing of the teeth
Study: NCT02609412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static compression of LMTRP
Description: Static compression of most sensitive Triggerpoint with a foam roller (Blackroll Inc., Germany).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic self-myofascial release of calf
Description: Dynamic self-massage of the calf with a foam roller (Blackroll Inc., Germany).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo laser acupuncture of LMTRP
Description: Used device: Laserneedle System (Laserneedle Systems GmbH, Glienicke/Nordbahn, Germany). Electrodes positioned on skin but device remains switched off.
Study: NCT02799238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALECSAT
Description: 3 doses of ALECSAT/4 weeks followed by ALECSAT/3 months
Study: NCT00661869

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Program
Description: 36 weeks of educational and supportive interventions
Study: NCT02193828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum
Description: Single injection into nodule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum
Description: Single injection into nodule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum
Description: Single injection into nodule

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single injection into nodule
Study: NCT03308162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral experiential group therapy
Description: The Kickstart Health Program is a Cognitive-Behavioral Experiential Therapy (CBET) that is administered via a person-centered group therapy format. Participants receive multiple therapeutic components that include psychoeducation, cognitive behavioral therapy, motivational interviewing, mindfulness, and acceptance and commitment therapy. Participants will also meditate and exercise in the group.
Study: NCT05551091

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glycomacropeptide (GMP)
Description: For each of the two baseline visits, women will consume a 300 calorie liquid breakfast meal tolerance test (MTT), eat a standard test lunch ad libitum with recording of food intake, and will then begin the low-dose GMP (25 g BID with meals) or high-dose GMP (25 g TID with meals) for 7 days. On day 7 of each GMP diet, women will come to the Clinical Research Unit (CRU) for a second breakfast MTT followed by lunch. All subjects will stop GMP products for 5-7 days (washout).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glycomacropeptide (GMP)
Description: For each of the two baseline visits, women will consume a 300 calorie liquid breakfast meal tolerance test (MTT), eat a standard test lunch ad libitum with recording of food intake, and will then begin the low-dose GMP (25 g BID with meals) or high-dose GMP (25 g TID with meals) for 7 days. On day 7 of each GMP diet, women will come to the Clinical Research Unit (CRU) for a second breakfast MTT followed by lunch. All subjects will stop GMP products for 5-7 days (washout).
Study: NCT04231955

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: numerical rating scale
Description: patients were asked to marked their pain intensity level on numerical rating scale between 0 and 10 and the result was recorded as pain intensity level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual analogue scale
Description: Patients were asked to marked their pain intensity level on visual analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possible. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: color analogue scale
Description: Patients were asked to marked their pain intensity level on color analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possibleand color change towards to worst pain possible end. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: faces rating scale
Description: Patients were asked marked their pain on a faces rating scale which consisted of six different faces representing different levels of pain intensity with the first face indicating no pain whilst last face indicating worst pain possible. The result was recorded as pain intensity level.
Study: NCT01771211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: anodal tDCS will be delivered with a constant current of 1 mA during resting-state and task-related fMRI and will continue until the end of the word-generation task. For both stimulation conditions (atDCS, sham) the current will be initially increased in a ramp-like fashion over 10 s, eliciting a tingling sensation on the scalp that fades over seconds. During sham stimulation the current will be turned off after 30 s.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: anodal tDCS will be delivered with a constant current of 1 mA during resting-state and task-related fMRI and will continue until the end of the word-generation task. For both stimulation conditions (atDCS, sham) the current will be initially increased in a ramp-like fashion over 10 s, eliciting a tingling sensation on the scalp that fades over seconds. During sham stimulation the current will be turned off after 30 s.
Study: NCT01677624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E7040
Description: E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
Study: NCT04238884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole preemptive genotyping strategy
Description: The patients who finally receives voriconazole will be randomized to receive the dose according to a pharmacogenetic algorithm including CYP2C19 genotype and clinical and demographic information.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole clinical practice
Description: The patients who finally receives voriconazole will be randomized to receive the dose according to clinical practice
Study: NCT01324934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG-Fresenius S
Description: Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory.~(In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of ATG-Fresenius treatment with 3 mg/kg/d at Day +6 and if deemed necessary also at Day +8 - but without corticosteroids).
Study: NCT05378022

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo Navax
Description: In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl physiological saline
Description: Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
Study: NCT03978104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Okara biscuits
Description: Consumption of okara-enriched biscuits together with habitual diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio-okara biscuits
Description: Consumption of bio-okara-enriched biscuits together with habitual diet. Bio-okara is a form of fermented okara.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control biscuits
Description: Consumption of control biscuits together with habitual diet.
Study: NCT02517853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham posterior tibial nerve stimulation
Study: NCT05238987

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate
Description: Single dose of ferrous sulphate (120 mg of elemental iron)
Study: NCT02963896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamicin
Description: intratympanic application of gentamicin 2m/80mg - 3x application -0,5 ml
Study: NCT01005056

Intervention type: DRUG
Intervention: Ethinylestradiol + Desogestrel
Description: All participants receive Marvelon® according to the approved dosage and administration method.
Study: NCT01481909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rupatadin
Description: 20 mg, 28 days over 60 days
Study: NCT02158819

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty with Visionaire
Description: Patient Specific Instrumentation
Study: NCT01393067

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-expandable plastic stent (plastic endoprosthesis)
Description: plastic stent (plastic endoprosthesis)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covered self-expandable metal stent (cSEMS)
Description: Removable, covered self-expandable metal stent (cSEMS)
Study: NCT04577924

Intervention type: OTHER
Intervention: Interview
Description: Trained research assistants would abstract the data as per a preset proforma. The data would be collected from the patient (if coherent), pre-hospital care provider or primary care provider.~Data would was also obtained from patient records and the proforma filled by the attending doctors on duty.~Follow up of cases would be done until discharge from the hospital.